MBOT, US59503A2042

Citizens sets USD 2.50 target for Microbot Medical stock

Published on 10/27/2026 at 19:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Microbot reports 44 patents on October 20, 2026. Microbot Medical stock costs EUR 0.93 on October 27, 2026 at 7:47 p.m. CEST in after-hours trading.

Analyst target and operating facts

Citizens initiated coverage with a USD 2.50 target on October 23, 2026.
Microbot Medical reported 44 issued patents and 49 pending applications on October 20, 2026.
Microbot Medical stock costs EUR 0.93 at Lang & Schwarz on October 27, 2026 at 7:47 p.m. CEST.
Second-quarter 2026 revenue reached USD 241,000, more than doubling from the prior quarter.

MBOT, US59503A2042, Illustration mit AI erstellt.

Citizens initiated coverage of Microbot Medical Inc. with a Market Outperform rating and a USD 2.50 price target on October 23, 2026, according to Investing.com. Against the Nasdaq quote of USD 1.03 on October 27, 2026, the target is 142.72 percent above the stock price. Microbot Medical was trading at EUR 0.93 at Lang & Schwarz on October 27, 2026 at 7:47 p.m. CEST.

Patent portfolio reaches 44

Microbot Medical said on October 20, 2026 that it had received multiple new patents, bringing its portfolio to 44 issued patents and 49 pending applications. The company linked the intellectual-property expansion to its LIBERTY endovascular robotic system and broader commercialization activity in the United States and international markets, according to its Microbot Medical press-release page.

Second-quarter revenue doubled

The latest reported operating figure came from the second quarter of 2026. Revenue reached USD 241,000, more than doubling from the previous quarter and exceeding H.C. Wainwright's USD 220,000 estimate, while the net loss was USD 5.6 million, or USD 0.08 per share, according to Investing.com. The revenue comparison is constructive, but the loss shows that commercialization still carries substantial execution risk.

Nasdaq range remains wide

Microbot Medical's Nasdaq quote was USD 1.03 on October 27, 2026 at 2:49 p.m. ET, with a market capitalization of USD 69.5 million and volume of 965,279 shares. Its 52-week range was USD 0.93 to USD 2.86, placing the quote USD 0.10 above the low and USD 1.83 below the high. The company develops robotic and computer-assisted technologies for minimally invasive endovascular procedures.

Analyst target meets commercialization risk

Citizens said the LIBERTY system is entering the early stages of commercialization and described execution risk as elevated because adoption remains at an early stage. The firm also cited the platform's disposable design and estimated 2028 sales of USD 22 million when setting its target on October 23, 2026. H.C. Wainwright separately maintained a Buy rating and a USD 12.00 target on October 21, 2026, according to Investing.com.

Microbot Medical stock in context

The combination of 44 issued patents, second-quarter revenue of USD 241,000 and a USD 2.50 Citizens target gives investors three measurable markers for the commercialization story. The Nasdaq quote remains close to its 52-week low, while the operating figures show early revenue growth alongside continuing losses.

Microbot Medical stock was trading at EUR 0.93 at Lang & Schwarz on October 27, 2026 at 7:47 p.m. CEST in after-hours trading. The further course of trading is shown by the continuously updated real-time quote of Microbot Medical stock.